Viking Therapeutics (VKTX) Total Non-Current Liabilities (2016 - 2025)
Viking Therapeutics (VKTX) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $318000.0 as the latest value for Q3 2025.
- Quarterly Total Non-Current Liabilities fell 57.88% to $318000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $318000.0 through Sep 2025, down 57.88% year-over-year, with the annual reading at $630000.0 for FY2024, 32.69% down from the prior year.
- Total Non-Current Liabilities hit $318000.0 in Q3 2025 for Viking Therapeutics, down from $410000.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.5 million in Q1 2022 to a low of $318000.0 in Q3 2025.
- Historically, Total Non-Current Liabilities has averaged $931266.7 across 4 years, with a median of $936000.0 in 2023.
- Biggest five-year swings in Total Non-Current Liabilities: decreased 20.74% in 2023 and later plummeted 57.88% in 2025.
- Year by year, Total Non-Current Liabilities stood at $1.3 million in 2022, then dropped by 25.71% to $936000.0 in 2023, then plummeted by 32.69% to $630000.0 in 2024, then crashed by 49.52% to $318000.0 in 2025.
- Business Quant data shows Total Non-Current Liabilities for VKTX at $318000.0 in Q3 2025, $410000.0 in Q2 2025, and $502000.0 in Q1 2025.